by admin, 0 Comments
Nawal Helmi1, Hani Choudhry1,2, Qari M3, Taha A Kumosani1,2,4,5, Abdulrahman L AL-Malki1,2,6, Said Salama Moselhy1,4,6,7, Afnan T Kumosani8
Background: The current study evaluated level of serum asymmetric dimethylarginine (ADMA) and its association to cardiac biomarkers in thalassemia patients for early diagnosis of abnormality in myocardial infarction.
Subjects and methods: This study was conducted on 80 subjects divided into four groups each with 20 subjects. Group I: Control: healthy subjects. Group II: Myocardial infarction: Patients with elevated serum troponin T. Group III: thalassemia patients. Group IV: thalassemia with myocardial infarction patients: Included 20 thalassemia patients with Myocardial infarction. Serum samples were subjected for assay of creatine kinase (CK:MB), Lactate dehydrogenase, troponin I ,ADMA, Serum MDA level was determined.
Results: Data obtained showed that serum CKMB, LDH1, AST, Troponin T and ADMA levels were significant elevated in MI with or without Thalassemia compared with control groups. Serum MDA was statistically significantly elevated in MI with or without Thalassemia compared with control groups. The serum level of troponin T showed an area under curve (AUC) of 0.92 ,(sensitivity 91.0 % and specificity, 88%). Also, the ADMA supported the diagnostic profile, showing an AUC of 0.85 with (sensitivity, 92.0%; specificity, 91,9%).
Conclusion: Serum ADMA is sensitive marker for incidence of MI in thalassemia patients.
Keywords: CKMB, LDH1, AST, Troponin T, asymmetric dimethylarginie, Thalassemia.
Cite as: Helmi N, Choudhry H, Qari M, Kumosani TA, AL-Malki AL, Moselhy SS, Kumosani AT. Association of serum asymmetric dimethyl-arginine and troponin I levels as a risk of myocardial infarction in thalassemia. Afri Health Sci. 2018;18(3): 720-726. https://dx.doi. org/10.4314/ahs.v18i3.30